Market Context — Why This Technology, Why Now

The global healthcare market is increasingly prioritizing preventive medicine and personalized health solutions, especially for chronic conditions. Consumers are seeking functional foods and supplements that offer proactive health benefits, while pharmaceutical companies are investing heavily in novel biological and gene-based therapies. This technology aligns perfectly with these trends, offering a versatile platform for both therapeutic and wellness applications, driving demand across diverse sectors.

Key Competitive Advantages
01

Enables fundamental inflammation suppression by directly targeting Regnase-1 mRNA structures, offering a novel mechanism.

02

Establishes strong market exclusivity with only one prior art reference cited by examiners, ensuring rapid technological advantage.

03

Expands application scope across pharmaceuticals, functional foods, supplements, and anti-inflammatory functional materials, enabling diverse market development.

Market Opportunity
Functional Foods and Supplements
$0.5B–$1.5B globally (AI est.)
Growing health consciousness and the importance of preventive medicine are expanding the demand for anti-inflammatory foods that can be consumed daily.
Major food and beverage corporations Dietary supplement manufacturers Health and wellness product developers
Pharmaceuticals and Regenerative Medicine
$500M–$1B globally (AI est.)
There is a strong demand for novel therapeutics for intractable inflammatory diseases, and this technology's unique mechanism of action could offer new treatment options.
Biopharmaceutical companies specializing in immunology Drug discovery firms targeting chronic diseases Biotech startups developing mRNA therapeutics
Cosmetics and Beauty
$250M–$500M globally (AI est.)
Inflammation suppression is a critical factor in addressing skin irritation and anti-aging concerns, making this technology a promising functional ingredient for cosmetic applications.
Global skincare and cosmetic brands Specialty ingredient suppliers for beauty products Dermatological product developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a composition targeting specific stem-loop structures of Regnase-1 mRNA, establishing a clear technical scope across 9 claims. Its robust patentability was proven through rigorous examination, including overcoming two office actions with only one prior art reference, indicating a low invalidation risk for licensees.

Competitive White Space

This patent primarily covers the composition and its mechanism of action. White space exists for licensees to develop novel delivery systems, specific product formulations (e.g., sustained-release forms), or diagnostic methods for identifying inflammation markers responsive to this mechanism.

Economic Impact
~$20M/year estimated new market creation potential (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

The functional food market for chronic inflammation-related products is estimated at ~$1B annually (AI est.). If functional foods incorporating this technology capture a 2% market share, an annual sales contribution of ~$20M (AI est.) is projected ($1B × 2% = $20M). Furthermore, if developed as a pharmaceutical, the potential for treatment cost reduction could multiply several times, leading to immeasurable long-term economic benefits.

Speed to Market
3× faster than in-house development
This technology's specific molecular mechanism for inflammation suppression is clearly defined in the patent claims, indicating that the foundational research phase is complete. The identification of a concrete target—specific stem-loop structures within Regnase-1 mRNA (Sequence ID No. 1 region)—significantly shortens the transition to product development compared to starting R&D from scratch. Kyoto University's willingness to grant licenses will further accelerate early commercialization.
Competitive Positioning

X: Novelty of Mechanism of Action
Y: Speed to Market

Business Models & Applications
🤝 Technology Licensing
Granting manufacturing and sales rights for this technology to existing pharmaceutical or food manufacturers, generating royalty income. Enables rapid market deployment.
🔬 Joint Research & Development
Collaborating with Kyoto University to jointly advance product development focused on specific inflammatory diseases or food sectors, leveraging academic expertise.
🏭 OEM Supply of Functional Ingredients
Developing functional ingredients with inflammation-suppressing effects based on this technology and supplying them as OEM raw materials for other companies' products, allowing broad industry expansion.
Adjacent Application Opportunities
👵 Elderly Care & Monitoring
Chronic Inflammation Care for Seniors
Develop functional foods or supplements utilizing this technology to address chronic inflammation, a key factor in declining senior QOL. Products could support joint health and gut microbiome improvement, potentially extending healthy lifespans by 5-10 years.
🐾 Pet Healthcare
Anti-Inflammatory Supplements for Animals
In the expanding pet healthcare market, this technology could develop supplements or functional foods for inflammatory conditions like arthritis, dermatitis, and allergies in pets. This offers a differentiated product to improve pet health and potentially extend their active lives by 2-3 years.
💡 Cosmetics & Beauty
Skincare for Inflammation & Anti-Aging
Skin inflammation contributes to issues like dryness, acne, sensitivity, and accelerated aging. Leveraging this technology's anti-inflammatory mechanism, high-performance skincare products or inner beauty supplements could target root causes of inflammation, potentially reducing visible signs of aging by 15-20%.
Integration Roadmap — Estimated 24-Month Deployment
Phase 1: Technology Evaluation & PoC
Duration: 5 months
Conduct detailed evaluation of the technology's foundational data and perform Proof of Concept (PoC) for target product categories. Assess applicability to existing product lines.
Phase 2: Prototype Development & Safety Testing
Duration: 11 months
Develop prototypes for selected product categories. Concurrently, plan and execute safety evaluations and initial efficacy tests for the composition.
Phase 3: Product Commercialization & Launch
Duration: 8 months
Refine prototypes and complete final safety and efficacy evaluations, then prepare for regulatory submissions. Following approval, initiate market launch based on marketing strategy.
Technical Feasibility
This technology is patented as a 'composition' that disrupts specific mRNA stem-loop structures, making it relatively easy to integrate into existing pharmaceutical manufacturing processes and functional food formulation techniques. Since the target molecule has been identified, no new large-scale basic research equipment investment is required, allowing development to proceed using existing R&D resources.
Success Scenario
Upon adopting this technology, licensees could introduce innovative products to the market that offer a fundamental approach to chronic inflammatory diseases, which have been challenging with conventional treatments. This could enable clear differentiation from competitors and establish new segments in the functional food and pharmaceutical markets. Ultimately, it is estimated to contribute to extending healthy lifespans and improving quality of life, while potentially increasing annual revenues by multiple digits.
Patent Record
APPLICATION NO.
特願2020-507894
REGISTRATION NO.
7258362
FILING DATE
2019/03/20
GRANT DATE
2023/04/07
EXPIRATION DATE
2039/03/20
PATENT HOLDER
国立大学法人京都大学
Examination History
2021年11月30日
手続補正書（方式）
2021年11月30日
出願審査請求書
2022年10月18日
拒絶理由通知書
2022年12月16日
意見書
2022年12月16日
手続補正書（自発・内容）
2023年02月07日
拒絶理由通知書
2023年02月28日
手続補正書（自発・内容）
2023年02月28日
意見書
2023年03月14日
特許査定